NEW YORK, May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NE ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...

Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Rich Eisenstadt - Chief Financial Officer Vipin Garg - President & Chief Executive Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Roger Song - Jefferies Alana Lelo - Guggenheim Mayank Mamtani - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen and welcome to Altimmune Inc. First Quarter 2024 Financi ...

Financial Performance - Altimmune reported cash, cash equivalents, and short-term investments of $182.1 million as of March 31, 2024[6]. - The net loss for Q1 2024 was $24.4 million, or $0.34 per share, compared to a net loss of $20.1 million, or $0.40 per share, in the same period in 2023[6]. - Interest income for Q1 2024 was $2.4 million, an increase from $1.7 million in Q1 2023, due to higher interest earned on cash equivalents[6]. - Total liabilities decreased to $15.4 million as of March 31, 2024, compared to $16.5 million at the end of 2023[14]. - Total stockholders' equity decreased to $172.9 million as of March 31, 2024, down from $194.1 million at the end of 2023[15]. Research and Development - Research and development expenses increased to $21.5 million for Q1 2024, up from $17.2 million in Q1 2023, with $13.5 million allocated to pemvidutide development[6]. - Enrollment is ongoing in the IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), targeting approximately 190 subjects[5]. - Top line results from the IMPACT trial are expected in Q1 2025, with primary efficacy measures focusing on MASH resolution or fibrosis improvement[5]. - In the MOMENTUM trial, 74.5% of weight loss in pemvidutide-treated subjects came from body fat, indicating effective fat reduction[4]. - The company plans to present a comprehensive data package at the End-of-Phase 2 meeting with the FDA, expected in late Q3 2024[5].

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/inv ...

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA)    Title: Focusing on the Use of GLP ...

GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected passing. Dr. Harrison's countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled ...

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity spending is e ...

Key PointsWegovy patients lost an average of 16% of their body weight against 2% for placebo users in clinical trials.Zepbound patients lost 20.9% body weight and up to 26% after 88 weeks compared to 9.5% for the placebo group, but dosages rose to 15 mg a week versus 2.4 mg for Wegovy.Both drugs are being researched for additional indications, including cardiovascular, MASH and neurological diseases.5 stocks we like better than Novo Nordisk A/SThe GLP-1 weight loss trend continues to flourish, and the ante ...

stockvisual/E+ via Getty Images Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company specializing in developing innovative peptide-based treatments for obesity and liver diseases, specifically Metabolic Dysfunction-Associated Steatohepatitis [MASH]. The company's drug candidate is Pemvidutide [ALT-801], which targets glucagon-like peptide-1 [GLP-1] and glucagon receptors to produce weight loss, keeping lean mass with reduced gastrointestinal side effects and cardiac events. Pemvidu ...